Novartis says remibrutinib meets primary endpoints in Phase 3 RMS trials, cuts relapse rate 35%

Novartis said remibrutinib met the primary endpoints in Phase 3 REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis (RMS), cutting the annualized relapse rate by 35.2% and 31.2% respectively versus a rival. The company plans to seek global approval for the drug in RMS.

Detected & updated continuously · Source: Nebula